Idorsia publishes a Financial Status required for an upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR
- Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company website
- Bondholder meeting now planned for early May as the company continues to engage with bondholders
Allschwil, Switzerland – April 17, 2024
Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the following link: http://www.idorsia.com/investors/financial-information
Idorsia continues to engage with bondholders on options and terms regarding the repayment of the convertible bond maturing on July 17, 2024 (ISIN: CH0426820350). As a result, the bondholder meeting initially contemplated for April 30, 2024, is expected to take place shortly thereafter.
André C. Muller, Chief Financial Officer, commented:
“We have had many interactions with our bondholders in the past week. We are finalizing our proposed amendment to the terms and conditions of the bond, taking into account the bondholder needs as well as our objective to avoid unnecessary dilution. We expect to publish the invitation to the bondholders meeting in the next few days.”
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer30.4.2024 00:40:00 CEST | Press release
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first antibody-drug conjugate (ADC) with demonstrated overall survival data to be granted full FDA approval in this patient population. The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial (NCT04697628), in which TIV
GOGL – 2024 AGM Results Notification29.4.2024 23:22:57 CEST | Press release
Golden Ocean Group Limited (the “Company”) advises that the 2024 Annual General Meeting of the Shareholders of the Company was held on April 29, 2024, at 16:30 hrs, at Hamilton Princess and Beach Club, 76 Pitts Bay Road, Hamilton HMCX, Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2023 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorized to fill such vacancies as and when it deems fit. To re-elect Ola Lorentzon as a Director of the Company. To re-elect John Fredriksen as a Director of the Company To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Ben Mills as a Director of the Company. To re-elect Cato Stonex as a Director of the Company. To re-appoint PricewaterhouseCoopers AS as a
SFL - 2024 AGM Results Notification29.4.2024 22:16:00 CEST | Press release
SFL Corporation Ltd. (NYSE: SFL) (“SFL” or the “Company”) advises that the 2024 Annual General Meeting of the Company was held on April 29, 2024, at 9:45 hours at Hamilton Princess and Beach Club, 76 Pitts Bay Road, Hamilton HMCX, Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2023, were presented to the Meeting. In addition, the following resolutions were passed: 1. To set the maximum number of Directors to be not more than eight. 2. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorised to fill such vacancies as and when it deems fit. 3. To re-elect Kathrine Fredriksen as a Director of the Company. 4. To re-elect Gary Vogel as a Director of the Company. 5. To re-elect Keesjan Cordia as a Director of the Company. 6. To re-elect James O’Shaughnessy as a Director of the Company. 7. To re-elect Ole Hjertaker as a Director of the Company. 8. To re-elect Wil
Nature’s Sunshine Recognized with Six Stevie Awards in the 2024 American Business Awards29.4.2024 22:05:00 CEST | Press release
LEHI, Utah, April 29, 2024 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products (Nasdaq: NATR), a leading natural health and wellness company of premium-quality herbal and nutritional products, received six Stevies—including three Gold Stevie Awards—in the 2024 American Business Awards. Gold Stevie Awards Saving Energy – Celebrating Nature’s Sunshine’s transition to 100% solar power at our U.S. manufacturing facility and additional efforts to reduce energy usage through increased efficiencies.Marketing Campaign of the Year – Health, Fitness & Wellness – Acknowledging the launch of the Power Line—Power Beets, Power Greens and Power Meal—as one of the most successful product launch campaigns in the company’s history.Human Resources Team of the Year – Recognizing the Nature’s Sunshine Human Resources team for its efforts to engage employees, foster leadership development and develop an award-winning culture. In addition to the Gold Stevies, the company was also recognized with two Silver Stevie
Nokia Corporation: Repurchase of own shares on 29.04.202429.4.2024 21:41:21 CEST | Press release
Nokia Corporation Stock Exchange Release 29 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 29.04.2024 Espoo, Finland – On 29 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,3003.44CEUX--BATE--AQEU--TQEX--Total385,3003.44 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of